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1639atrial repolarization and increased AF inducibility in
a pig model for sleep apnea, indicating an interac-
tion between the acetylcholine (ACh)-induced atrial
effective refractory period shortening and the re-
duced activation of the sympathetic nervous system
after RDN. Consistently, ACh-mediated AF was facil-
itated by isoproterenol, which decreased the thres-
hold of ACh concentration for AF induction and
increased AF duration in dogs (3).
The proposal to combine different approaches to
modulate the autonomic nervous system is indeed
attractive. However, pre-clinical studies indicate that
the inﬂuence of autonomic nervous system modula-
tion on AF is complex and does not automatically
result in antiarrhythmic effects. As an example, baro-
receptor stimulation at an intensity that reduces heart
rate increases AF susceptibility (4), whereas low-level
stimulation can display antiarrhythmic effects (5).
Whether a combination of 2 approaches to modulate
the autonomic systems results in antiarrhythmic or
arrhythmogenic effects is difﬁcult to predict and
needs to be elucidated in future studies.*Stephan H. Schirmer, MD, PhD
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31:767–74.Post-Percutaneous
Coronary Intervention
Angina
A New Performance Measure?The recently published DUTCH PEERS (DUrable
polymer-based sTent CHallenge of Promus Element
Versus ReSolute Integrity; TWENTE II trial (1) utilizes
an important endpoint for percutaneous coronary
intervention (PCI) studies: “post-PCI angina.” We
congratulate the authors for reporting this important
outcome. This comparative effectiveness study eval-
uated 2 third-generation drug-eluting stents (DES)
with respect to this patient-reported outcome mea-
sure (PROM). At 1-year follow-up, there was no
difference between treatments, with over 80% of
patients in both groups being angina-free. This com-
pares favorably with other PCI studies reporting this
PROM, including the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive DruG
Evaluation) (2) (57%), SYNTAX (Synergy between
PCI with Taxus and Cardiac Surgery) (3) (72%), and
FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease) (4) (79%) trials. If post-
PCI angina is to become a commonly reported
PROM, a better understanding of its determinants is
required.
Variability in the post-PCI angina outcome may
arise from differences in patient, angiographic, inter-
ventional, and measurement factors. Patient factors
include risk factors such as diabetes (where angina
sensation is impaired), the clinical presentation (post-
PCI angina may be less common in acute coronary
syndromes), and the baseline angina frequency.
Angiographic and interventional factors that describe
the extent of coronary artery disease and complete-
ness of revascularization are also important. Whether
it is a coincidental observation or an important
determinant, the type of stent may be relevant
because the COURAGE, SYNTAX, FREEDOM, and
DUTCH PEERS studies represent a transition from
bare-metal stents to ﬁrst- and second-generation DES,
respectively, with reports of increasing angina-free
status at 12 months.
Measurement factors for the assessment of post-
PCI angina are especially important and worthy of
further consideration in interpreting the DUTCH
PEERS study. First, ensuring that the measure is
“patient-reported” rather than “clinician-reported”
is important because these have been shown to
Letters to the Editor J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 2 , 2 0 1 5
O C T O B E R 2 0 1 5 : 1 6 3 8 – 4 4
1640differ (5). The empiric 4-graded scale used appears to
be “patient-reported”; however, it is unclear whether
the “mild, moderate, or severe physical effort”
description was clinician-directed. As the major
endpoint was “angina free,” this is of less importance
in this particular discussion. A second consideration
is the observation time course; that is, does “angina-
free at 12 months” infer no pain over the entire 12
months or no pain in the month prior to the 12-month
interval? The latter is often utilized, but it is unclear
in the present study. Finally, has the DUTCH PEERS
4-category post-PCI angina scale been validated? The
studies described previously (2–4) have utilized the
Seattle Angina Questionnaire (SAQ), which has been
shown to be reproducible in patients with stable
angina, responsive to PCI, and validated with short-
acting nitrate consumption. These characteristics
need to be detailed for the DUTCH PEERS angina scale
to assist with interpretation of the results. Further-
more, the SAQ was not used because it was too long;
however, the short version (SAQ-7) would have been
appropriate.
Thus, the future evolution of evaluating post-PCI
angina requires the use of established validated
measures as well as detailed documentation of the
patient, angiographic, and interventional factors that
may inﬂuence this important PROM. The measure-
ment of this endpoint is fundamental and should be
incorporated into all PCI studies, particularly because
it is often the primary reason the patient initially
sought medical attention.Rosanna Tavella, BSc(Hons), PhD
Isuru Ranasinghe, MBBS, MMed (Clin Epi), PhD
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Intervention Angina: A New Performance
Measure?We welcome the opportunity of responding to the
letter by Dr. Tavella and colleagues and expand on
the chest pain assessment in the DUTCH PEERS (DU-
rable polymer-based sTent CHallenge of Promus
ElemEnt versus ReSolute Integrity; TWENTE II) study
(1). As a matter of fact, the pain score used is
straightforward and leans on routine clinical practice.
Patients were asked whether they still experienced
chest pain (referring to the last few weeks) and to
individually grade the level of physical activity when
having pain. This approach reﬂects that, for many
patients, it is most important to be symptom-free
during ordinary activities, because this ensures an
independent, self-determined life. The majority of
patients provided the information through a postal
questionnaire, whereas a telephone follow-up (same
questions) and/or consultation of medical records
was performed in much lower proportions of patients.
Hence, it is fair to address these data as patient-
reported.
The short version of the well-deﬁned and validated
Seattle Angina Questionnaire (SAQ), the SAQ-7, may
certainly be an interesting instrument to assess
angina and its consequences, but it still comprises 7
questions (2). Because the PAPAYA (PAtient Prefer-
ence Analysis of Yearly follow-up After PCI) study
recently revealed that patients prefer #6 to 10 follow-
up questions (3), and aspects other than chest pain/
angina need to be addressed (e.g., adverse events,
hospitalization, medication), SAQ-7 may still be
borderline large for use in all-comer studies.
The chest pain score in DUTCH PEERS is very short,
simple, and related to the patient’s individual ﬁt-
ness and performance. It does not measure angina
but rather evaluates patient-reported chest pain,
which is—albeit not exclusively—a key symptom of
angina. There was no distinction between typical and
atypical chest pain because both affect the patient’s
performance, may trigger further cardiac assess-
ment, and increase the costs of medical care. Because
the approach used in the DUTCH PEERS study
was not validated against antianginal medication,
a comparison with the SAQ might seem appealing.
